Immunotherapy drug shows promise in keeping lung cancer at bay
NCT ID NCT03706690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether the immunotherapy drug durvalumab can help people with stage III non-small cell lung cancer that hasn't grown after chemoradiation. About 400 participants receive either durvalumab or a placebo every 4 weeks. The goal is to see if durvalumab delays cancer progression and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug)
What this could lead to
If successful, this could offer a new standard treatment to help keep stage III lung cancer from growing after initial chemoradiation.
What could go wrong
This is a late-stage trial, but durvalumab may not work for everyone and can cause immune-related side effects. Results may not apply to all lung cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Shanghai, 200030, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, 200433, China
-
Research Site
Shenyang, 110042, China
-
Research Site
Ürümqi, 830000, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Yangzhou, 225001, China
-
Research Site
Zhengzhou, 450000, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Hong Kong, 00000, Hong Kong
-
Research Site
Bangalore, 560068, India
-
Research Site
Bengaluru, 560076, India
-
Research Site
Karamsad, 388325, India
-
Research Site
Kolkata, 700160, India
-
Research Site
Nashik, 422005, India
-
Research Site
Vadodara, 390007, India
-
Research Site
Culiacán, 80230, Mexico
-
Research Site
Mexico City, 0 3100, Mexico
-
Research Site
Mexico City, 11810, Mexico
-
Research Site
México, 1400, Mexico
-
Research Site
Monterrey, 64000, Mexico
-
Research Site
Beijing, 100021, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100730, China
-
Research Site
Beijing, 100853, China
-
Research Site
Bengbu, 233004, China
-
Research Site
Changchun, 130000, China
-
Research Site
Changchun, 510000, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chengdu, 610042, China
-
Research Site
Chengdu, 610072, China
-
Research Site
Chongqing, 400037, China
-
Research Site
Fuzhou, 350011, China
-
Research Site
Guangzhou, 510280, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310006, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150081, China
-
Research Site
Linhai, 317000, China
-
Research Site
Nanjing, 210009, China
-
Research Site
Nanning, 530021, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Qingdao, 266042, China
-
Research Site
San Luis Potosí City, 78250, Mexico
-
Research Site
Bacolod, 6100, Philippines
-
Research Site
Baguio City, 2600, Philippines
-
Research Site
Cagayan de Oro, 9000, Philippines
-
Research Site
Cebu, 6000, Philippines
-
Research Site
Davao City, 8000, Philippines
-
Research Site
Quezon City, 1100, Philippines
-
Research Site
Quezon City, 1104, Philippines
-
Research Site
San Juan City, 1502, Philippines
-
Research Site
Bialystok, 15-540, Poland
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Poznan, 60-569, Poland
-
Research Site
Tomaszów Mazowiecki, 97-200, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Kazan, Tatarstan, 420029, Russia
-
Research Site
Kirov, 610021, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 121467, Russia
-
Research Site
Murmansk, 183047, Russia
-
Research Site
Novosibirsk, 630055, Russia
-
Research Site
Novosibirsk, 630099, Russia
-
Research Site
Obninsk, 249036, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Samara, 443031, Russia
-
Research Site
Saransk, 430005, Russia
-
Research Site
Volgograd, 400138, Russia
-
Research Site
Daegu, 41944, South Korea
-
Research Site
Gwangju, 61469, South Korea
-
Research Site
Seoul, 08308, South Korea
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Taipei, 114, Taiwan
-
Research Site
Taipei, 235, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Adana, 01060, Turkey (Türkiye)
-
Research Site
Ankara, 06340, Turkey (Türkiye)
-
Research Site
Edirne, 22030, Turkey (Türkiye)
-
Research Site
Istanbul, 34030, Turkey (Türkiye)
-
Research Site
Konya, 42080, Turkey (Türkiye)
-
Research Site
Malatya, 44100, Turkey (Türkiye)